Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.78 |
| ▸ | TP53 | P04637 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | CASP1 | P29466 | 1/20 | 0.69 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.64 |
| ▸ | P4HB | P07237 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15783216 | 0.90 | MAPT (0.82) | MAPTTP53LMNAKDM4EHTT | |
| SCHEMBL26241620 | 0.89 | MAPT (0.81) | MAPTTP53LMNAKDM4EHTT | |
| SCHEMBL2153383 | 0.89 | MAPT (0.83) | MAPTTP53LMNAKDM4EHTT | |
| SCHEMBL31023243 | 0.88 | MAPT (1.00) | MAPTTP53LMNAKDM4EHTT | |
| SCHEMBL2153142 | 0.88 | MAPT (1.00) | MAPTTP53LMNAKDM4EHTT | |
| SCHEMBL2154016 | 0.88 | MAPT (0.78) | MAPTTP53LMNAKDM4EHTT | |
| SCHEMBL31023282 | 0.88 | MAPT (0.81) | MAPTTP53LMNAKDM4EHTT | |
| SCHEMBL2153278 | 0.88 | MDM2 (0.79) | MAPTTP53LMNAKDM4EHTT | |
| SCHEMBL15783135 | 0.86 | MAPT (1.00) | MAPTTP53LMNAKDM4ETDP1 | |
| SCHEMBL15870279 | 0.85 | MAPT (0.81) | MAPTTP53LMNAKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | Zacharon Pharmaceutical, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011082175-A2 | GLYCOSAMINOGLYCAN INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| EP-2307440-A2 | HEPARAN SULFATE INHIBITORS | Zacharon Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100048638-A1 | HEPARAN SULFATE INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048638-A1 | HEPARAN SULFATE INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048638-A1 | HEPARAN SULFATE INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2010003023-A2 | HEPARAN SULFATE INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003023-A2 | HEPARAN SULFATE INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | CSGALNACT1, FUT5, ST3GAL3 | MAPT 4328/4885TP53 3840/4885LMNA 3422/4885 |
| US-20100048638-A1 | HEPARAN SULFATE INHIBITORS | HPSE, ENGASE, CSGALNACT1 | MAPT 4276/4885TP53 4477/4885LMNA 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.